Human papillomavirus (HPVs) are circular, double-stranded DNA viruses, which are known for the development of cervical, oropharyngeal, anal, vulvovaginal, and penile cancers. HPV-associated carcinogenesis provides a classical model system for RNA interference (RNAi) based cancer therapies, because the viral oncogenes causes cancers expressed only in cancerous cells.

• Cavisiran (LNP based-HPV siRNA drug) demonstrates a novel therapeutic approach for combined HPV-E6/E7 oncogene silencing and apoptosis induction via restoration of TP53/ Rb tumor suppressor gene function.
• Cavisiran maximizes its therapeutic effectiveness by combining prescription with chemotherapy and radiation therapy.
• EnhancedBio has confirmed the in vitro and in vivo efficacy of the final siRNA candidate for its potential off-target effects. It is designed to be used in combination with the concurrent chemoradiotherapy.